Global AI Wire
For a family, the question is direct: Can this patient access the treatment? Inside a biotechnology company, that request may open several clinical, regulatory, and commercial pathways. In conversation with cardiologist Tiago Bignoto, biotechnology executive Dorian Readnour explains why science changes lives only when leadership, clinical expertise, and patient experience connect early.
Inside a biotechnology company, the request immediately becomes more complex. 'That is one question to us. That is three, maybe four questions,' Readnour said. Is the physician asking about a clinical trial, expanded access, or commercial access after approval? Each route involves different teams, evidence, rules, and timelines.
The gap between corporate pathways and clinical urgency highlights why breakthroughs often fail to transform patient lives. Discovery must become credible evidence; regulators and payers must recognize value; and health systems must deliver care. A failure at any point leaves families navigating fragmented systems designed for mass treatment, not personalized care.
Readnour, with international experience in biotechnology, rare disease, strategy, and patient access, focuses on bridging these gaps. Her career has shown how business goals and ethical care can advance together. Approval alone is insufficient if diagnosis is delayed, physicians lack preparation, reimbursement is unavailable, or patients face barriers to access.
Bignoto, a cardiologist and founder of The Valve Club, approaches the challenge through clinical practice, research, and physician education. Their shared conclusion: science, execution, and patient experience must operate as one to achieve real-world impact.
A structural mismatch exists: companies organize work by functions, while physicians prioritize clinical urgency. Families experience lost time due to fragmented pathways. Historically, requests were passed between departments, each addressing only its part. A better model requires a clear point of entry routing requests to the appropriate pathway—trial, expanded access, or commercial access.
The problem is not just administrative; it’s a leadership question. Who is responsible for seeing the patient’s entire journey when institutions focus on their own segments?
Readnour’s philosophy shifts how executives define success. Approval is not enough if diagnosis is delayed, physicians unprepared, reimbursement unavailable, or patients cannot find the right access point.
Bignoto’s perspective begins earlier in the chain. A promising hypothesis must be tested through rigorous trial design and evidence strong enough to guide care. In rare diseases, patients may be few, centers dispersed, and meaningful outcomes years away. Industry can contribute capital, technical expertise, and operational scale, but clinical leaders must define the problem before a development plan is fixed.
Physicians can assess whether the right patients can be found, whether endpoints measure meaningful benefit, and whether clinical infrastructure can use innovations safely. Development and access leaders must explain what evidence regulators and payers will require, where barriers differ, and which decisions affect viability at scale.
The role of a key opinion leader (KOL) becomes more consequential. Bignoto describes the KOL not as a name attached to a finished technology but as an independent scientific bridge connecting development, validation, medical communities, and patient care. Such dialogue can expose assumptions that appear coherent inside a corporate plan but fail in practice.
The strongest collaboration is not endorsement but challenging questions, evidence, and paths to implementation while there is still time to change them.
Local expertise is critical. A centralized model can spread lessons, but barriers in São Paulo may differ sharply from those in Moldova. Physicians from Croatia and Australia may recognize common scientific questions while working within different diagnostic, regulatory, and reimbursement realities. Local clinicians show where pathways fail; executive teams must translate these signals into decisions about evidence, partnerships, investment, and implementation.
Physician networks like The Valve Club can circulate evidence, compare experiences, and surface questions a single institution might miss. However, speed is not a substitute for judgment. Trusted clinical leaders must distinguish evidence from enthusiasm and translate research without reducing it to promotion.
Readnour notes that governments, payers, clinicians, and families may not value the same outcomes. In progressive diseases, conventional measures can miss changes that matter profoundly to daily life. Patient voice should determine which questions are asked, which outcomes are measured, and which compromises are acceptable.
Patient stories are among the most effective ways to make unmet needs visible in strategic discussions. Data describes the size of a problem; lived experience reveals its consequences. Both are necessary to shape research, services, and investment around outcomes that matter beyond a spreadsheet.
The same principle applies to time. Some therapies aim to prevent losses that may not become visible for years. Natural-history data, registries, biomarkers, and trial designs suited to small populations can help identify change earlier without lowering the standard of evidence.
Readnour’s vision for the next decade includes earlier diagnosis, better measures of effectiveness, and greater investment in the next generation of physicians. If knowledge remains concentrated in a few centers, discovery will move faster than the health system’s ability to apply it.
Bignoto describes the same future as one in which integration becomes routine: 'It is a collaborative effort where everyone speaks the same language.' Physicians understand research and access; scientists work closer to clinical decisions; executives listen to local signals before global strategies are fixed; and patients participate before success has been narrowly defined.
Technology, including artificial intelligence, may help identify overlooked patients and clinical signals earlier. Its value depends on the system around it—the evidence, professionals, institutions, and decisions that turn a signal into care.
At the end of the conversation, Readnour said she and Bignoto had approached the problem from different directions but found that their 'goals, aims, and hopes are very similar.' That convergence is the work of innovation itself: connecting scientific possibility with leadership, clinical judgment, and local capability required to make it real for a patient.
Source: reuters.com
